GlassScriptPhysician profile
Ronald G Campos
NPI 1366505778
$9,793.65
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,225 · 2020: $2,614 · 2021: $2,871 · 2022: $760 · 2023: $896 · 2024: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,446.13 | 2019-2023 | Xarelto |
| Abbvie INC. | $1,001.57 | 2021-2023 | Ubrelvy, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $915.42 | 2019-2024 | Jardiance |
| Allergan, INC. | $901.31 | 2019-2020 | |
| Pfizer INC. | $670.80 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $447.33 | 2019-2023 | Farxiga, Breztri |
| Collegium Pharmaceutical, INC. | $428.49 | 2019-2022 | |
| Glaxosmithkline, LLC. | $365.14 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $348.02 | 2021 | |
| Astellas Pharma US INC | $323.73 | 2019-2024 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $270.22 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.19 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $212.50 | 2019-2020 | |
| Daiichi Sankyo INC. | $181.81 | 2019-2022 | |
| Eisai INC. | $173.21 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $168.85 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $166.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $85.31 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $82.46 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $72.90 | 2019-2021 | |
| Lilly USA, LLC | $71.92 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.48 | 2021 | |
| Novo Nordisk INC | $40.56 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $39.98 | 2024 | Hetlioz |
| Ironwood Pharmaceuticals, INC | $38.37 | 2019 | |
| Idorsia Pharmaceuticals US INC | $38.01 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $22.71 | 2023 | Gvoke Hypopen |
| Alfasigma USA, INC. | $12.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.